Bristol-Myers Squibb Co
XHAM:BRM

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
XHAM:BRM
Watchlist
Price: 46.38 EUR -0.93%
Market Cap: €102.9B

Net Margin

12.6%
Current
Improving
by 7.8%
vs 3-y average of 4.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
12.6%
=
Net Income
$6B
/
Revenue
$48B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
12.6%
=
Net Income
€6B
/
Revenue
$48B

Peer Comparison

Country Company Market Cap Net
Margin
US
Bristol-Myers Squibb Co
NYSE:BMY
111.3B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
529.7B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
222B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...

Market Distribution

Higher than 72% of companies in the United States of America
Percentile
72nd
Based on 15 072 companies
72nd percentile
12.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Bristol-Myers Squibb Co
Glance View

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BRM Intrinsic Value
60.05 EUR
Undervaluation 23%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
12.6%
=
Net Income
$6B
/
Revenue
$48B
What is Bristol-Myers Squibb Co's current Net Margin?

The current Net Margin for Bristol-Myers Squibb Co is 12.6%, which is above its 3-year median of 4.7%.

How has Net Margin changed over time?

Over the last 3 years, Bristol-Myers Squibb Co’s Net Margin has decreased from 14.3% to 12.6%. During this period, it reached a low of -18.5% on Dec 31, 2024 and a high of 18.4% on Sep 30, 2023.

Back to Top